Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.89 |
| ▸ | STS | P08842 | 8/20 | 0.89 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.89 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.89 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.89 |
| ▸ | SHBG | P04278 | 1/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.89 |
| ▸ | PGR | P06401 | 1/20 | 0.89 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.89 |
| ▸ | AR | P10275 | 1/20 | 0.89 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.89 |
| ▸ | SNCA | P37840 | 1/20 | 0.89 |
| ▸ | HTR2B | P41595 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone SCHEMBL22847 | 0.99 | STS (0.91) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL6693553 | 0.99 | STS (0.91) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL22551313 | 0.98 | STS (0.89) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL8901907 | 0.98 | STS (0.89) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL5553656 | 0.95 | CYP19A1 (0.97) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL4747162 | 0.95 | CYP19A1 (0.97) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL628643 | 0.94 | STS (0.87) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL157262 | 0.94 | CYP19A1 (1.00) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL12054811 | 0.94 | CYP19A1 (1.00) | STSHSD17B1CYP19A1LMNAMAPT | |
| Estrone SCHEMBL7831317 | 0.94 | CYP19A1 (1.00) | STSHSD17B1CYP19A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111579523-B | Method for rapidly detecting conjugated estrogens in pregnant mare urine by near infrared spectroscopy | 新疆新姿源生物制药有限责任公司 | 2024-03-08 | — | — | CN | claimed |
| CN-111458442-B | Method for measuring content of conjugated estrogen in pregnant mare urine | 新疆新姿源生物制药有限责任公司 | 2022-08-12 | — | — | CN | claimed |
| US-20220206019-A1 | NEAR-INFRARED (NIR) QUALITY MONITORING METHOD USED IN COLUMN CHROMATOGRAPHY FOR EXTRACTING CONJUGATED ESTROGENS (CEs) FROM PREGNANT MARE URINE (PMU) | XINJIANG MEDICAL UNIVERSITY (CN) | 2022-06-30 | — | — | US | claimed |
| CN-112748200-A | Near-infrared quality monitoring method for column chromatography process for obtaining conjugated estrogen component from pregnant mare urine | 新疆医科大学 | 2021-05-04 | — | — | CN | claimed |
| CN-111579523-A | Method for rapidly detecting content of conjugated estrogens in pregnant mare urine by using near infrared spectroscopy | 新疆新姿源生物制药有限责任公司 | 2020-08-25 | — | — | CN | claimed |
| US-20170232002-A1 | COMMERCIAL SCALE PRODUCTION METHODS FOR TRANSDERMAL HORMONE FORMULATIONS | ANIP ACQUISITION COMPANY | 2017-08-17 | — | — | US | claimed |
| US-8247393-B2 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | TEVA WOMEN'S HEALTH, INC. (US) | 2012-08-21 | — | — | US | claimed |
| US-8217024-B2 | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof | TEVA WOMEN'S HEALTH, INC. (US) | 2012-07-10 | — | — | US | claimed |
| WO-2012024361-A1 | COMMERCIAL SCALE PRODUCTION METHODS FOR TRANSDERMAL HORMONE FORMULATIONS | BIOSANTE PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | claimed |
| US-20120046264-A1 | COMMERCIAL SCALE PRODUCTION METHODS FOR TRANSDERMAL HORMONE FORMULATIONS | BIOSANTE PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | US | claimed |
| WO-2000041700-A1 | USE OF ESTROGENS AND DELTA-GONADIEN-21-OL-3,20-DIONES IN THE TREATMENT OR PROPHYLAXIS OF CEREBRAL DEGENERATIVE DISORDERS | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | claimed |
| WO-2000041701-A1 | USE OF ESTROGENS AND DELTA-GONADIEN-21-OL-3,20-DIONES FOR TREATING INSULIN DEPENDENT AND NON-INSULIN DEPENDENT DIABETES | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | claimed |
| WO-1999058524-A1 | BENZOCARBAZOLE AND INDENOINDOLE DERIVED ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | claimed |
| US-5861431-A | Incontinence treatment | IOTEK, INC. (US) | 1999-01-19 | — | — | US | claimed |
| EP-0831772-A2 | INTRAURETHRAL PHARMACOTHERAPY OF INCONTINENCE | IOTEK, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040054-A2 | INTRAURETHRAL PHARMACOTHERAPY OF INCONTINENCE | IOTEK, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0424954-B1 | Pharmaceutical composition for treatment of osteoporosis | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | claimed |
| US-5116828-A | Estrogen and thyroid hormone | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1992-05-26 | — | — | US | claimed |
| EP-0424954-A1 | Pharmaceutical composition for treatment of osteoporosis | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1991-05-02 | — | — | EP | claimed |
| US-4154820-A | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers | AKZONA INCORPORATED (US) | 1979-05-15 | — | — | US | claimed |